share_log

BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $24

Benzinga ·  Nov 10, 2023 15:01

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price target from $25 to $24.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment